Pharmafile Logo
Pharmafocus logo
Advanced Search

Sales and Marketing

Showing 15 posts of 11527 posts found.

Merck sales fall in Q1 despite new product lifts

April 29, 2015 Sales and Marketing Merck, Q1, Remicade

Merck’s sales were down in the first quarter of 2015 thanks to its consumer care divestment and increasing competition for …
News

GSK shingles vaccine performs

April 29, 2015 Research and Development, Sales and Marketing GSK, GlaxoSmithKline, HZ/su, Merck, zostovax

GlaxoSmithKline’s HZ/su vaccine candidate for the prevention of shingles has demonstrated promising benefits across all age groups in a late-stage …
News

Conference round-up: companies go big on hepatitis C at EASL

April 29, 2015 Sales and Marketing Bristol-Myers Squibb, EASL, Merck, daclatasvir, daklinza

Big pharma names posted favourable results for hepatitis C treatments as they jostled for position as market leaders at the …
News

RSA hires two consultants in Germany

April 29, 2015 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Andreas Reimer, Ji Kwon, rsa

Executive search and interims firm RSA has appointed two consultants to its teams in the DACH region. Andreas Reimer (pictured) …
Appointment

Helping Nepal – SHL to Match Staff Donations

April 29, 2015 Sales and Marketing helping nepal, shl group, world vision

In immediate response to the devastating earthquake that left Nepal in ruins on April 25th, SHL quickly reached out to …
News
Press release

BMS lifted by new products

April 28, 2015 Sales and Marketing BMS, NICE, Q1, eams, immuno-oncology and hepatitis C

New drugs have helped Bristol-Myers Squibb see a slight increase in sales for the first quarter of 2015. Total revenues …
News

Celgene splashes out on cancer R&D firm

April 28, 2015 Research and Development, Sales and Marketing

Oncology specialists Celgene have made a $485 million outlay to buy Quanticel Pharmaceuticals, to increase its effort and investment in …
News

UK ‘has ten years to become global biotech leader’

April 28, 2015 Manufacturing and Production, Research and Development, Sales and Marketing

The UK should be home to ‘the third global cluster’ for biotech in the next 10 years, according to a …
News

M&A drama continues as Mylan rejects Teva

April 28, 2015 Sales and Marketing M&A, MA, Mylan, Perrigo, Teva, bids, generics, takeovers

Mylan has firmly rejected Teva’s acquisition bid, even though its own bid for Irish firm Perrigo has also been turned …
News

Researchers hit out at ‘alarming’ increase in MS drug costs

April 27, 2015 Manufacturing and Production, Research and Development, Sales and Marketing

Researchers have hit out at the ‘alarming’ rise in the costs of disease-modifying treatments for multiple sclerosis, in a new …
News

Big-name generics among new CHMP recommendations

April 27, 2015 Sales and Marketing CHMP, EMA, European Medicines Agency, Lyrica, pregabalin

The EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended 11 new medicines for approval, among them several …
News

The Pharmafocus debate: Is the price of new hepatitis C treatments fair?

April 27, 2015 Research and Development, Sales and Marketing Doctors of the World, Drug pricing, EFPIA, Gilead, MSF, drug cost, hepatitis C, patents, sofosbuvir, sovaldi

YES – says Richard Bergström, director general of the European Federation of Pharmaceutical Industries and Associations (EFPIA), who argues that …
Feature

EMA approves BMS’ Opdivo for advanced skin cancer

April 27, 2015 Sales and Marketing BMS, Bristol-Myers Squibb, EMA, Merck, Yervoy, ipilimumab, keytruda, melanoma, nivolumab, opdivo, pembrolizumab, skin cancer

Bristol-Myers Squibb has earned a recommendation from the EMA for its cancer immunotherapy treatment Opdivo as a monotherapy for patients …
News

AstraZeneca looks to oncology match-ups to boost sales

April 24, 2015 Sales and Marketing AstraZeneca, Brilinta, Celgene, Innate, Juno, farxiga, ticagrelor

AstraZeneca posted a 1% increase in revenue in its first-quarter 2015 financials – and is investing the money to back …
News

Clinigen buys Idis for £225 million

April 24, 2015 Sales and Marketing CBPE Capital, Clinigen, IDIS, unlicensed

UK speciality pharma group Clinigen is paying £225 million to acquire the Surrey-based unlicensed supplier of medicines firm Idis. Unlicensed …
News
The Gateway to Local Adoption Series

Latest content

Scots neonatal innovations target hearing loss and earlier care

August 28, 2026

FDA grants De Novo authorisation to light-filtering device for migraine

August 28, 2026

Southgate opens Innovation Lab for logistics and fulfilment development

August 27, 2026

Bioptimus partners with Cancer Research Horizons to expand AI cancer data set

August 27, 2026

Agentis Health Group acquires Clinical Pharmacist Solutions

August 26, 2026